Navigation Links
Pharmacyclics Reports Second Quarter 2013 Results
Date:7/31/2013

I study of ibrutinib in combination with bendamustine and rituximab in patients with R/R CLL/SLL. This trial is a randomized, multi-center, double-blinded, placebo-controlled trial of ibrutinib in combination with bendamustine and rituximab versus placebo in combination with bendamustine and rituximab in R/R CLL/SLL patients who received at least one line of prior systemic therapy. The primary endpoint of the study is to demonstrate a clinically significant improvement in PFS when compared to bendamustine and rituximab. This global study, conducted by Janssen, is recruiting and Janssen plans to enroll 580 patients worldwide.
  • NCI STUDY: Phase III study of ibrutinib alone compared to ibrutinib in combination with rituximab or compared to rituximab in combination with bendamustine in treatment naive older CLL patients. This trial is a randomized trial of ibrutinib in treating patients 65 years or older with previously untreated CLL and is being initiated by the National Cancer Institute (NCI). The primary endpoint of the study is PFS. This study is not yet recruiting and the NCI plans to enroll 523 patients.
  • MCL

  • SPARK (MCL2001): Phase II study of ibrutinib in patients with R/R MCL who progressed after bortezomib therapy. This is a single-arm, multi-center trial of ibrutinib as a monotherapy in R/R MCL patients who received at least one prior rituximab-containing chemotherapy regimen and who progressed after bortezomib therapy. The primary endpoint of the study is ORR, which is scheduled to be evaluated 6 months from the completion of enrollment. This global study, conducted by Janssen, has completed enrollment of the planned 110 patients in April 2013.
  • RAY (MCL3001): Phase III study of ibrutinib versus temsirolimus in R/R MCL patients. This trial is a randomized, multi-center, open-label trial of ibrutinib as a monotherapy versus temsirolimus in R/R MCL patients who received at least one prior rituximab-containing chemotherapy regi
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
    2. Pharmacyclics Reports First Quarter 2013 Results
    3. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
    4. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
    5. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
    6. Pharmacyclics, Inc. Prices Public Offering of Common Stock
    7. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
    8. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
    9. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
    10. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
    11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... , Dec. 24, 2014  Diplomat Pharmacy, Inc. ... specialty pharmacy, is proud to announce Jennifer Hagerman ... at Diplomat, will take office as the president of ... formal induction ceremony will take place Feb. 28, 2015, ... be held at the Renaissance Center in ...
    (Date:12/24/2014)... Echo Therapeutics, Inc. (NASDAQ: ... skin permeation, continuous glucose monitoring and associated technologies, ... has been appointed Chief Executive Officer effective December ... years of experience in the medical device, pharmaceutical ... as Vice President, Business Development, Otsuka Pharmaceuticals as well ...
    (Date:12/24/2014)... , Dec. 23, 2014   Synageva BioPharma ... biopharmaceutical company developing therapeutic products for rare disorders, ... (EMA) of the Marketing Authorization Application (MAA) for ... granted the company,s request for accelerated assessment, which ... review time.   The MAA, and ...
    Breaking Medicine Technology:Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
    ... 20, 2011 Orexigen® Therapeutics, Inc. (Nasdaq: ... with senior officials in FDA,s Office of New Drugs ... requirements for a cardiovascular outcomes trial (CVOT) for Contrave® ... in January 2011. Orexigen believes that these design requirements ...
    ... Sept. 20, 2011 Misonix, Inc. (NASDAQ: ... designs, manufactures and markets innovative therapeutic ultrasonic products ... surgery, and other surgical and medical applications, today ... and year ended June 30, 2011.  Michael A. ...
    Cached Medicine Technology:Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 2Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 3Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 4Orexigen and FDA Identify a Clear and Feasible Path to Approval for Contrave® 5Misonix Reports Fourth Quarter and Year-End Fiscal 2011 Financial Results 2Misonix Reports Fourth Quarter and Year-End Fiscal 2011 Financial Results 3Misonix Reports Fourth Quarter and Year-End Fiscal 2011 Financial Results 4Misonix Reports Fourth Quarter and Year-End Fiscal 2011 Financial Results 5Misonix Reports Fourth Quarter and Year-End Fiscal 2011 Financial Results 6Misonix Reports Fourth Quarter and Year-End Fiscal 2011 Financial Results 7Misonix Reports Fourth Quarter and Year-End Fiscal 2011 Financial Results 8
    (Date:12/26/2014)... “Many people become overwhelmed by the ... issues and phone calls with insurance companies,” The Jones ... their free eBook on pedestrian and bicycle accidents ... and bicycle auto accident claims assures the injured individual ... professionally handling their case while they focus on recovering. ...
    (Date:12/26/2014)... December 26, 2014 Parker & ... the best in heating, cooling and plumbing contractor ... hour emergency services in 2014 with regard to ... that Arizona is known for its incredibly hot ... understands the intricacies and details of a wide ...
    (Date:12/25/2014)... 2014 The report “Nintedanib (Colorectal ... focuses on the current treatment landscape, unmet needs, ... cancer market. Stivarga is a drug which is ... cancer. Boehringer Ingelheim is developing nintedanib (BIBF-1120), an ... refractory CRC in the US, Europe, and Japan. ...
    (Date:12/25/2014)... 26, 2014 Recently, iFitDress.com, the popular online ... has announced its new selection of black one-shoulder cocktail ... sale now; they are available at discounted prices, up to ... promotion will last for three weeks only. You know, we ... who are interested in our new items can visit our ...
    (Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
    Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
    ... Lancet has called for immediate changes in the approval processes ... came after the trial of TGN1412 ended in disaster with ... ,The journal says that since the ... trial, it is the agency’s responsibility to review the protocol. ...
    ... bird flu threat. ,According to Dr. Anthony Fauci, ... is // going to be so intense that it is ... of situation we see everywhere from Nigeria to Indonesia." ... bird flu has killed 109 people in nine countries, mostly ...
    ... in China have performed the country's first face transplant, and ... ,A surgical team at the Xijing hospital in Xi'an replaced ... disfigured after a bear mauled him two years ago, Zhang ... ,"The surgery is even more complex than the first ...
    ... who receive healthy hearts from donors 50 years of age and ... from younger patients, according to a University Of Alberta study//. This ... March-April 2006 issue. ,The study ... of age and older and found that there were no major ...
    ... study conducted by researchers has highlighted that most of the ... as required// for follow up tests done to evaluate the ... 436 men who underwent vasectomy at the Cleveland Clinic, Ohio, ... sperm-checking tests, that played a crucial role in conferring an ...
    ... have found that applying antiviral coating on bank notes, ... in fighting the epidemics//. ,Materials researcher Guagang ... discovered a coating of metal, metal oxide and ceramic ... edition of New Scientist. ,Applying the ...
    Cached Medicine News:Health News:Good news: there is no threat of bird flu confirms US 2Health News:Men Unaware of Fertility Status After Vasectomy 2
    The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
    The Antibacterial Personal Catheter® features a unique silicone composition that provides an antibacterial coated soft outer layer of silicone combined with a firm inner layer....
    The Uro San® Plus male external catheter is a latex catheter with a double-sided adhesive and Shield Skin Protective Dressing....
    ... Mentor Freedom Pak Seven Starter ... week's supply of Freedom Clear ... all 100% latex-free ... for your convenience and comfort. ...
    Medicine Products: